Page 7 - Initiate Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHannah deresiewiczKim brazzellJill steierHead of researchDrug delivery technologyDrug administrationKala pharmaceuticals incExchange commissionAssociation to prevent blindnessAssociation for researchKala pharmaceuticalsClinical developmentDemonstrate rapidComplete wound healingPatients achieving complete healing

Moleculin Reports Full Year Financial Results and Provides Programs Update

– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine.

United statesUnited kingdomCity ofJenene thomasWalter klempMoleculin biotech incCompany investigational new drugDrug administrationRiverside ethics committeeRiverside research ethics committeeExchange commissionPrnewswire moleculin biotech incSecurities exchangeHealthcare products regulatory agencyAcute myeloid leukemiaSoft tissue sarcoma

Landos Biopharma Reports Fourth Quarter and Full Year 2021

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year .

Roger adsettLandos biopharmaChris garabedianTim maylebenDevelopment expensesClinical development updatesLandos biopharma incProgress towards optimizing clinical developmentInitiate phaseUlcerative colitis laterUlcerative colitisNormal healthy volunteersTop line resultsBoth studies expectedInterim presidentLandos board

Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of. | March 24, 2022

Roger adsettLandos biopharmaWilkinson brimmer katcherChris garabedianTim maylebenJoele frankExchange commissionDevelopment expensesClinical development updatesLandos biopharma incProgress towards optimizing clinical developmentInitiate phaseUlcerative colitis laterUlcerative colitisNormal healthy volunteersTop line results

Indaptus Therapeutics Announces Appointment of Boyan Litchev, M D as Chief Medical Officer

Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer - read this article along with other careers information, tips and advice on BioSpace

Boyan litchevJeffreya mecklerOncology at quintiles internationalIndaptus therapeutics incFerring pharmaceuticalsClinical team leaderHead of clinical development oncologyIonis pharmaceuticalsUniversity plovdivMedical leadershipClinical oncologyInitiate phaseChief medical officerChief executive officerSenior vice presidentGlobal clinical development oncology